Matches in SemOpenAlex for { <https://semopenalex.org/work/W2589533368> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W2589533368 endingPage "319" @default.
- W2589533368 startingPage "319" @default.
- W2589533368 abstract "319 Background: CTCs from patients (pts) at different clinical stages were analyzed by a never explored experimental approach based on a combination of two techniques. Provision of this information may contribute to optimize tailored therapies. Methods: 3 cohorts were analyzed: pts with muscle-invasive bladder cancer receiving neoadjuvant (NA) sorafenib + chemotherapy (CT) (NCT01222676), and metastatic (M1) pts receiving 1st-line MVAC, and 2nd-line (M2) anti-TGFβ receptor ALK1 PF-03446962 (NCT01620970). 5 ml of whole blood were filtered by ScreenCell Cyto devices and CTC status was assessed with centralized scoring by referral pathologists. Additional 5 ml of whole blood were processed by immunomagnetic beads (AdnaTestSelect kit) and the expression level of a panel of markers (including EPCAM and MUC1) was studied using RT-multiplex PCR. The objective was the association with clinical response/relapse. Results: From 07/2012 to 08/2013, 48 pts (17 NA, 17 M1, and 14 M2) were enrolled. Rates of baseline CTC+ were: 91, 77, 75% (ScreenCell), and 36, 41, 69% with AdnaTest, respectively. NA setting: from baseline to post-CT, all pts had a stepwise reduction of CTC count/5 ml blood by ScreenCell (median baseline of 15 [0-40] to 0 [0-3]). Increase in circulating EPCAM±MUC1 levels by CTC was seen in accordance with the 3 disease progressions (PD). M1 setting: Pts who relapsed had a median of 25 CTC/5 ml (IQR: 12-47) at the end of CT, while all the others had levels <10. EPCAM profile was concordant in all cases (median 1.10 vs 0.42 ng/µl). Despite classified as partial/complete responders by RECIST criteria, 5/7 cases with >6 month follow-up displayed an increase in EPCAM levels and CTC number which anticipated a relapse. M2 setting: increase in CTC signals from baseline to +2 months was observed in 8/9 evaluable cases by AdnaTest and 4/5 evaluable cases by ScreenCell, in accordance with PD. Conclusions: This combined technique showed a promising ability to anticipate the detection of clinical relapse, although it still needs a larger sample size. Refining molecular characterization will help designing informed clinical trials." @default.
- W2589533368 created "2017-03-03" @default.
- W2589533368 creator A5005962316 @default.
- W2589533368 creator A5012466586 @default.
- W2589533368 creator A5016673044 @default.
- W2589533368 creator A5030934542 @default.
- W2589533368 creator A5048310964 @default.
- W2589533368 creator A5058849092 @default.
- W2589533368 creator A5067994961 @default.
- W2589533368 creator A5080811290 @default.
- W2589533368 creator A5083331837 @default.
- W2589533368 creator A5086507632 @default.
- W2589533368 creator A5089021391 @default.
- W2589533368 creator A5090061046 @default.
- W2589533368 creator A5090715927 @default.
- W2589533368 date "2014-02-01" @default.
- W2589533368 modified "2023-10-17" @default.
- W2589533368 title "Quantification and molecular profiling of circulating tumor cells (CTCs) in urothelial cancer (UC) before and during systemic treatment: Implications across the clinical stages." @default.
- W2589533368 doi "https://doi.org/10.1200/jco.2014.32.4_suppl.319" @default.
- W2589533368 hasPublicationYear "2014" @default.
- W2589533368 type Work @default.
- W2589533368 sameAs 2589533368 @default.
- W2589533368 citedByCount "0" @default.
- W2589533368 crossrefType "journal-article" @default.
- W2589533368 hasAuthorship W2589533368A5005962316 @default.
- W2589533368 hasAuthorship W2589533368A5012466586 @default.
- W2589533368 hasAuthorship W2589533368A5016673044 @default.
- W2589533368 hasAuthorship W2589533368A5030934542 @default.
- W2589533368 hasAuthorship W2589533368A5048310964 @default.
- W2589533368 hasAuthorship W2589533368A5058849092 @default.
- W2589533368 hasAuthorship W2589533368A5067994961 @default.
- W2589533368 hasAuthorship W2589533368A5080811290 @default.
- W2589533368 hasAuthorship W2589533368A5083331837 @default.
- W2589533368 hasAuthorship W2589533368A5086507632 @default.
- W2589533368 hasAuthorship W2589533368A5089021391 @default.
- W2589533368 hasAuthorship W2589533368A5090061046 @default.
- W2589533368 hasAuthorship W2589533368A5090715927 @default.
- W2589533368 hasConcept C121608353 @default.
- W2589533368 hasConcept C126322002 @default.
- W2589533368 hasConcept C126894567 @default.
- W2589533368 hasConcept C143998085 @default.
- W2589533368 hasConcept C2776677690 @default.
- W2589533368 hasConcept C2778019345 @default.
- W2589533368 hasConcept C2778695046 @default.
- W2589533368 hasConcept C2779013556 @default.
- W2589533368 hasConcept C2780352672 @default.
- W2589533368 hasConcept C61238886 @default.
- W2589533368 hasConcept C71924100 @default.
- W2589533368 hasConcept C90924648 @default.
- W2589533368 hasConceptScore W2589533368C121608353 @default.
- W2589533368 hasConceptScore W2589533368C126322002 @default.
- W2589533368 hasConceptScore W2589533368C126894567 @default.
- W2589533368 hasConceptScore W2589533368C143998085 @default.
- W2589533368 hasConceptScore W2589533368C2776677690 @default.
- W2589533368 hasConceptScore W2589533368C2778019345 @default.
- W2589533368 hasConceptScore W2589533368C2778695046 @default.
- W2589533368 hasConceptScore W2589533368C2779013556 @default.
- W2589533368 hasConceptScore W2589533368C2780352672 @default.
- W2589533368 hasConceptScore W2589533368C61238886 @default.
- W2589533368 hasConceptScore W2589533368C71924100 @default.
- W2589533368 hasConceptScore W2589533368C90924648 @default.
- W2589533368 hasIssue "4_suppl" @default.
- W2589533368 hasLocation W25895333681 @default.
- W2589533368 hasOpenAccess W2589533368 @default.
- W2589533368 hasPrimaryLocation W25895333681 @default.
- W2589533368 hasRelatedWork W2111304055 @default.
- W2589533368 hasRelatedWork W2147244189 @default.
- W2589533368 hasRelatedWork W2287945026 @default.
- W2589533368 hasRelatedWork W2504155562 @default.
- W2589533368 hasRelatedWork W2600551723 @default.
- W2589533368 hasRelatedWork W2811050112 @default.
- W2589533368 hasRelatedWork W3034078793 @default.
- W2589533368 hasRelatedWork W3046289049 @default.
- W2589533368 hasRelatedWork W4214929818 @default.
- W2589533368 hasRelatedWork W2118673085 @default.
- W2589533368 hasVolume "32" @default.
- W2589533368 isParatext "false" @default.
- W2589533368 isRetracted "false" @default.
- W2589533368 magId "2589533368" @default.
- W2589533368 workType "article" @default.